2Yamamoto M, Oshiro S, Tsugu H, et al. Treatment of recurrent malignant supratentorial astrcoytomas with carboplatin and etoposide combined with recombinant mutant human tumor necrosis factor-alpha[ J]. Anticancer Res, 2002, 22(4) : 2447-2453.
3Tomita A, Fuchino Y, Otsuka K, et al. Clinical effects of exogenous/endogenous TNF therapy on metastatic lesions of 34 colorectal cancer patients[J]. Anticancer Res, 1998, 18(5D): 3937-3939.
1Alison L J,Peter S.Clinical applications of tumour necrosis factor[J].Progress in Growth Factor Research,1989,1(2):107-122.
2Yamamoto M,Oshiro S,Tsugu H,et al.Treatment of recurrent malignant supratentorial astrocytomas with carboplatin and etoposide combined with recombinant mutant human tumor necrosis factor alpham[J].Anticancer Res,2002,22(4):2447-2453.
3Tomita A,Fuchino Y,Otsuka K,et al.Clinical effects of exogenous/endogenous TNF therapy on metastatic lesions of 34 colorectal cancer patients[J].Anticancer Res,1998,18(5D):3937-3939.
4Cheson B,Horning S,Coiffer B,et al.Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma[J].J Clin Oncol,1999,17(4):1244-1253.
